

# MGCD-265 analog

Catalog No: tcsc0188



## Available Sizes

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

875337-44-3

**Formula:**

$C_{26}H_{20}FN_5O_2S_2$

**Pathway:**

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

**Target:**

c-Met/HGFR;VEGFR

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

517.6

## Product Description


MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential

antineoplastic activity with IC<sub>50</sub> of 29 nM and 10 nM for c-Met and VEGFR2, respectively.

IC<sub>50</sub> value: 10 nM (VEGFR2), 29 nM (c-Met) [1]

Target: VEGFR, c-Met

in vivo: MGCD-265-analog has a reasonable half-life, 1.2 h in rats and 5.8 h in dogs, and has an acceptable clearance, 0.33 L/(kg h) in rats and 1.1 L/(kg h) in dogs. The steady state volume of distribution was low in rats (0.25 L/kg) and reasonable in dogs (1.5 L/kg), while the oral bio-availability was determined to be 12% and 42% in rats and dogs, respectively. GCD-265-analog performed well in vivo against a panel of different human tumor types, particularly those that are driven by or overexpress c-Met (MNNGHOS and MKN45). Tumor growth inhibition at a dose of 20 mg/kg po once daily ranged from 41% to 94%. MGCD-265-analog was found to show spill-over inhibition of a number of kinases in addition to the intended c-Met/VEGFR2 activity. MGCD-265-analog has significant antitumor activity in vivo.[1]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!